

Special Issue

Diagnosis and Control of African Swine Fever Virus (ASFV) Infection

Message from the Guest Editors

African swine fever (ASF) is currently the most threatening disease in domestic and wild pigs worldwide for which there is no commercial vaccine available. The presence of ASF on five continents, including large parts of Asia, makes ASF the worst livestock pandemic of this century. The causal agent, the African swine fever virus (ASFV), is a large and highly complex virus that affects both domestic and wild pigs, such as European and African wild pigs, making it difficult to eradicate in endemic areas with the coexistence of circulating viruses of different virulence. The purpose of this special issue of *Vaccines* is to update knowledge and research on important aspects of the disease related to virus infection, disease dynamics, diagnostic tools, and control strategies. Particular emphasis will be placed on research focused on studies with new vaccine candidates, including the elucidation of vaccine control strategies.

Guest Editors

Dr. Marisa Arias

European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Dr. Carmina Gallardo

European Union Reference Laboratory for ASF and FAO Reference Centre for ASF, Centro de Investigación en Sanidad Animal CISA-INIA/CSIC, Valdeolmos, 28130 Madrid, Spain

Deadline for manuscript submissions

closed (31 July 2025)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/119567

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).